The Mar­tin Shkre­li saga ends to­day, but the is­sue he raised on drug pric­ing seems im­mor­tal

Mar­tin Shkre­li is of­fer­ing us one last les­son to­day on the con­se­quences of crim­i­nal­ly bad be­hav­ior.

A fed­er­al judge, al­ready riled enough by Shkre­li’s de­ci­sion to of­fer a boun­ty on Hillary Clin­ton’s hair to leave him locked up in a Brook­lyn prison for 6 months to await sen­tenc­ing and then force him to for­feit $7.4 mil­lion, will sen­tence him lat­er to­day on three felony con­vic­tions.

In the end, Shkre­li tried to strike an apolo­getic tone for his trans­gres­sions. He had lied re­peat­ed­ly to his in­vestors, ma­nip­u­lat­ed Retrophin stock and feared jail. But pros­e­cu­tors on­ly threw back a damn­ing se­ries of re­marks he had made mock­ing his en­e­mies, and proud­ly de­clar­ing that he was about to get off near­ly scot free, hap­py to do some short time in Club Fed. They al­so ridiculed his pre­ten­sions about drug de­vel­op­ment, high­light­ing an un­su­per­vised drug tri­al in Cyprus.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.